Saanroo announced that Levagen®+, its highly bioavailable palmitoylethanolamide (PEA) ingredient, has won two 2026 NutraIngredients Awards, further cementing its standing as one of the industry’s most extensively researched PEA ingredients.
Levagen+ received the NutraIngredients USA Innovation in Women’s Health Award and, in May 2026, was named Ingredient of the Year: Healthspan at the NutraIngredients Europe Awards, highlighting the ingredient’s growing body of clinical evidence and versatility across multiple health applications. Presented annually, the NutraIngredients Awards recognize the nutrition industry’s most innovative ingredients, companies, and scientific achievements worldwide. Winners are selected by an independent panel of industry experts based on scientific excellence, innovation, commercial relevance, and demonstrated impact.
“These awards are especially meaningful because they recognize the quality of the science behind Levagen+,” said Maggie McNamara, Vice President of Global Marketing at Saanroo. “From the beginning, Saanroo’s goal has been to develop ingredients backed by rigorous human clinical research that deliver on their health benefits. Receiving recognition in two award categories validates its long-term commitment to scientific innovation.”
Levagen+ is a highly bioavailable form of palmitoylethanolamide (PEA), an endocannabinoid-like lipid naturally produced by the body that helps support a healthy inflammatory balance and cellular function. Manufactured with Pharmako Biotechnologies’ patented LipiSperse® delivery technology, Levagen+ improves dispersion and bioavailability, helping formulators maximize ingredient performance across diverse formats.
Unlike ingredients supported by a single area of research, Levagen+ has been evaluated in more than 18 published human clinical studies investigating benefits across a wide range of health applications, including:
- Women’s health, including menstrual comfort, stress, relaxation, and quality of life
- Healthy aging and mobility
- Joint comfort and physical function
- Exercise recovery
- Sleep quality
- Cognitive performance
- Immune health
- Healthy inflammatory response
“Consumers and brands alike are seeking ingredients backed by meaningful science,” said John Quilter, CEO. “Levagen+ reflects that shift by combining innovative delivery technology with a robust and expanding body of human clinical research. These awards recognize not only what the ingredient has achieved today but also its continued potential to support future product innovation.”
The latest recognitions further reinforce Saanroo’s commitment to advancing science-backed wellness solutions and to investing in clinical research that helps customers differentiate their products in an increasingly competitive marketplace.
To learn more about Levagen®+ and its clinical backing, visit www.LevagenPlus.com or www.Saanroo.com.
